Record Date 01/27/2016
FEI Number 1000120535
Firm Name New England Home Therapies Inc.
Record Type 483
State MA
Establishment Type Producer of Sterile Drug Products
Similar Posts
Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
FOR IMMEDIATE RELEASE – Nov. 6,2025 – LAKE ZURICH, Ill.— Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is voluntarily recalling three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection, USP, 20 mgInotiv Inc. – 10/24/2025
Inotiv Inc. – 10/24/2025. Country: United States. Record Type: 483FDA Drug Competition Action Plan
FDA’s Drug Competition Action Plan (DCAP) encourages robust and timely market competition for generic drugs and helps bring greater efficiency and transparency to the generic drug review process, without sacrificing the scientific rigor underlying our generic drug program.Friendly’s Issues Allergy Alert on Undeclared Soy/Wheat in Friendly’s Cookies & Cream Ice Cream
Friendly’s Ice Cream is voluntarily recalling a limited quantity (324 cartons) of 48 fl. oz. Cookies & Cream ice cream because of undeclared soy and wheat. The recalled product was mistakenly packaged in Friendly’s Vanilla Bean ice cream cartons with a Cookies & Cream lid. People who have an allergyTopical Antiseptic Products: Hand Sanitizers and Antibacterial Soaps
This page outlines the deferral requests and advice letters issued by FDA to manufacturers of over-the-counter (OTC) topical antiseptic products. These products are categorized as either consumer or health care and they include rubs and washes.FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
The U.S. Food and Drug Administration today established a “green list” import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.
